Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | April 24, 2026 | April 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date April 24, 2026 · Filed April 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.92 · Expires 2036-04-24 | Direct | 51,280 |
Reported balance
After 2026-04-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-24 · Grant · Acquired 51,280 · Balance 51,280 F1: The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2026 Filed Apr 28, 2026 20:24 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 51,280 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001104659-26-050391 · tm2612896-2_4seq1.xml · derivative · entry 1 Gilmer Daniel B. · CIK 0002122703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,280 Underlying: Common Stock · 51,280 shares Expires 2036-04-24 F1 · derivative.exercise_date: The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.